Eltrombopag and romiplostim are TPO-RAs, which have been approved by the Food and Drug Administration (FDA) and proposed for the treatment of ITP patients with persistent disease (≥3 months), who are corticosteroid-dependent or unresponsive to corticosteroids [31]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.